H3K27ac coinhibition augmented the efficacy of EZH2 inhibitors and also triggered the MAPK pathway in some cancers, signifying that the blockade of EZH2 resulted in a feedback stimulation of certain signaling pathways in a context-dependent manner (Figure 2) [112, 113]. Here, EZH2 is linked to cancer.